Indication: Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease
Sub-indication: Alzheimer's Disease
Study Type: Drug Study
Principal Investigator: Greg Cooper, M.D. Ph.D.Norton Neuroscience Institute
Sponsor: Sponsor: Eli Lilly
Learn more at ClinicalTrials.gov
Email for more information: NNIResearch@nortonhealthcare.org
